Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bo Abrahamsen

Showing results (31-40 of 211) with videos related to

Pageof 22
Sort By:
Nature Reviews. Rheumatology|May 15, 2013
The role of vitamin D supplementation in patients with rheumatic diseasesBo Abrahamsen, Nicholas C Harvey
Ugeskrift for Laeger|March 13, 2009
[Alendronate for the prevention and treatment of postmenopausal osteoporosis. A survey of a Cochrane review]Pia A Eiken, Bo Abrahamsen
Ugeskrift for Laeger|March 5, 2010
[Assessment and treatment of osteoporotic hip fractures]Pia A Eiken, Bo Abrahamsen
Ugeskrift for Laeger|January 12, 2017
[Osteoporosis treatment can be discontinued based on an individual assessment]Pia A Eiken, Bo Abrahamsen
Current Osteoporosis Reports|February 2, 2021
Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?Douglas C Bauer, Bo Abrahamsen
Bone|February 28, 2012
Beyond a reasonable doubt? Bisphosphonates and atypical femur fracturesBo Abrahamsen, Thomas A Einhorn
The Journal of Clinical Endocrinology and Metabolism|May 15, 2023
New Insights in the Pathophysiology, Epidemiology, and Response to Treatment of Osteoporotic Vertebral FracturesMichael Kriegbaum Skjødt, Bo Abrahamsen
The Journal of Clinical Endocrinology and Metabolism|September 17, 2010
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysisBo Abrahamsen, Pia Eiken, Richard Eastell
Rheumatology (Oxford, England)|July 11, 2013
Safety issues with bisphosphonate therapy for osteoporosisErnest Suresh, Michael Pazianas, Bo Abrahamsen
Current Opinion in Molecular Therapeutics|December 24, 2005
Technology evaluation: denosumab, AmgenBo Abrahamsen, Andy Y T Teng
Pageof 22

Showing results (31-40 of 211) with videos related to

Sort By:
Pageof 22
Nature Reviews. Rheumatology|May 15, 2013
The role of vitamin D supplementation in patients with rheumatic diseasesBo Abrahamsen, Nicholas C Harvey
Ugeskrift for Laeger|March 13, 2009
[Alendronate for the prevention and treatment of postmenopausal osteoporosis. A survey of a Cochrane review]Pia A Eiken, Bo Abrahamsen
Ugeskrift for Laeger|March 5, 2010
[Assessment and treatment of osteoporotic hip fractures]Pia A Eiken, Bo Abrahamsen
Ugeskrift for Laeger|January 12, 2017
[Osteoporosis treatment can be discontinued based on an individual assessment]Pia A Eiken, Bo Abrahamsen
Current Osteoporosis Reports|February 2, 2021
Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?Douglas C Bauer, Bo Abrahamsen
Bone|February 28, 2012
Beyond a reasonable doubt? Bisphosphonates and atypical femur fracturesBo Abrahamsen, Thomas A Einhorn
The Journal of Clinical Endocrinology and Metabolism|May 15, 2023
New Insights in the Pathophysiology, Epidemiology, and Response to Treatment of Osteoporotic Vertebral FracturesMichael Kriegbaum Skjødt, Bo Abrahamsen
The Journal of Clinical Endocrinology and Metabolism|September 17, 2010
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysisBo Abrahamsen, Pia Eiken, Richard Eastell
Rheumatology (Oxford, England)|July 11, 2013
Safety issues with bisphosphonate therapy for osteoporosisErnest Suresh, Michael Pazianas, Bo Abrahamsen
Current Opinion in Molecular Therapeutics|December 24, 2005
Technology evaluation: denosumab, AmgenBo Abrahamsen, Andy Y T Teng
Pageof 22